(TMCI) Treace Medical Concepts - Ratings and Ratios

Treace Medical Concepts, Inc. (NASDAQ:TMCI) is a medical technology company specializing in the design, development, and commercialization of innovative orthopedic devices. The company focuses on addressing foot and ankle deformities, particularly bunions, through its proprietary Lapiplasty® platform. Its flagship product, the Lapiplasty 3D Bunion Correction System, is a comprehensive solution that combines precision instruments, anatomically designed implants, and advanced surgical techniques to correct bunions in three planes of deformity. This approach aims to provide more accurate and durable outcomes compared to traditional bunion correction methods. Additionally, the company offers the Lapiplasty Mini-Incision system, which enables surgeons to perform the Lapiplasty procedure through a smaller 3.5cm incision, potentially reducing recovery time and improving patient comfort. Treace also markets the Adductoplasty system, a solution designed for reproducible realignment, stabilization, and fusion of the midfoot, addressing complex deformities beyond bunions.

Founded in 2013 and headquartered in Ponte Vedra, Florida, Treace Medical Concepts has established itself as a leader in the foot and ankle surgery space. The companys products are supported by extensive clinical data and are designed to address the limitations of traditional bunion surgeries, such as incomplete correction and recurrence of deformities. Treaces focus on innovation, coupled with its commitment to improving patient outcomes, has positioned it as a key player in the orthopedic device market. The company continues to expand its product portfolio and surgical techniques, further solidifying its position in the growing foot and ankle surgery market.

Ticker Symbol: TMCI
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Health Care Equipment

Average Volume 20d: 392,910
Last Price: $9.13
SMA 20: $9.95
SMA 50: $8.79
SMA 200: $6.92
ATR: $0.54

Market Cap: $601.79M USD
P/E: 0.00
P/E Forward: 0.00
P/B: 5.97
P/S: 2.97
RoE: -58.65%

3-Month Forecast:
Based on the provided data, TMCI shares are expected to experience volatility, with price movements influenced by technical and fundamental factors. The stock is currently trading below its 20-day and 50-day moving averages, suggesting near-term downward pressure. However, the 200-day moving average indicates longer-term bullish momentum. The relatively high ATR of $0.54 signals potential price swings. Fundamentally, the companys negative RoE and high P/B ratio reflect ongoing investment in growth initiatives, which may impact short-term profitability but could drive long-term value creation. The market cap and P/S ratio suggest investor confidence in the companys growth prospects despite current losses.